Trinity Biotech (Trinity Biotech) Total Stockholders Equity : $-17.49 Mil (As of Sep. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Trinity Biotech Total Stockholders Equity?

Trinity Biotech's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-17.49 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Trinity Biotech's Book Value per Share for the quarter that ended in Sep. 2023 was $-2.29. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Trinity Biotech's Debt-to-Equity for the quarter that ended in Sep. 2023 was -3.83.

Trinity Biotech Total Stockholders Equity Historical Data

The historical data trend for Trinity Biotech's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trinity Biotech Total Stockholders Equity Chart

Trinity Biotech Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Stockholders Equity

Get a 7-Day Free Trial

44.05

4.71

-2.22

-0.32

-2.18

Trinity Biotech Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Stockholders Equity	Get a 7-Day Free Trial															6.63	-2.18	-6.62	-11.38	-17.49

Trinity Biotech (NAS:TRIB) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Trinity Biotech's Book Value per Share for the quarter that ended in Sep. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(-17.487	-	0)	/	7.64151
	=	-2.29

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Trinity Biotech's Debt-to-Equity for the quarter that ended in Sep. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.81	+	65.205)	/	-17.487
	=	-3.83

Trinity Biotech Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Trinity Biotech's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Trinity Biotech (Trinity Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Trinity Biotech PLC (NAS:TRIB) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

TRBA:Germany

Address

IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8

Website

https://www.trinitybiotech.com

Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Rest of World - Ireland of which it derives a majority of its revenues from the Americas segment.